SCHEMBL24815345

SCHEMBL24815345

Cc1ccccc1[C@H]1CCCCC1=O

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.53
CRBN Q96SW2 1/20 0.53
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MCL1 Q07820 1/20 0.41
HTR2C P28335 2/20 0.41
MAPT P10636 4/20 0.40
TLR4 O00206 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15874850 1.00 DDB1 (0.53) DDB1CRBNALDH1A1KDM4EHSD17B10
SCHEMBL4132442 1.00 DDB1 (0.53) DDB1CRBNALDH1A1KDM4EHSD17B10
SCHEMBL29973239 1.00 DDB1 (0.53) DDB1CRBNALDH1A1KDM4EHSD17B10
SCHEMBL2329301 0.95 DDB1 (0.54) DDB1CRBNALDH1A1KDM4EHSD17B10
SCHEMBL27998909 0.80 CYP1A2 (0.41) DDB1CRBNKDM4EMCL1MAPT
SCHEMBL27173350 0.80 CA1 (0.41) DDB1CRBNMCL1MAPTTLR4
SCHEMBL30496227 0.79 NPC1 (0.38) ALDH1A1KDM4EHSD17B10TLR4CA1
SCHEMBL1617366 0.79 NPC1 (0.38) ALDH1A1KDM4EHSD17B10TLR4CA1
SCHEMBL1617179 0.79 CA1 (0.43) ALDH1A1MCL1MAPTTLR4CA1
SCHEMBL22566680 0.79 MCL1 (0.41) KDM4EMCL1MAPTTLR4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409555-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS INC (US) 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409555-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS HTR2C, PNMT, HTR2A DDB1 1270/4885CRBN 1752/4885ALDH1A1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.